CLINICAL TRIALS PROFILE FOR SILVADENE
✉ Email this page to a colleague
All Clinical Trials for SILVADENE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01297400 ↗ | Phase 2, Open Label, Randomized, Active Controlled Pilot Study MW-III vs Silver Sulfadiazine Second Degree Thermal Burns | Not yet recruiting | Skingenix, Inc. | Phase 2 | 2022-01-12 | To compare MW-III to Silvadene® Cream 1% (Silver Sulfadiazine) with respect to "time to healing" in second-degree thermal burns |
| NCT04601532 ↗ | Superficial Partial-Thickness Burn Study | Recruiting | Synedgen, Inc | Phase 4 | 2021-06-11 | This study is an investigator initiated, single site, University of Pittsburgh, prospective, parallel group, randomized controlled trial comparing SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel (intervention group) to the current gold standard treatment Silvadene (control group). Both groups will receive the same care other than the treating agent. Subjects will be recruited form the UPMC Mercy Burn Center adult patient pool who have sustained superficial partial-thickness burn wounds that comprise less than or equal to 10% of total body surface area (TBSA) |
| NCT04601532 ↗ | Superficial Partial-Thickness Burn Study | Recruiting | United States Department of Defense | Phase 4 | 2021-06-11 | This study is an investigator initiated, single site, University of Pittsburgh, prospective, parallel group, randomized controlled trial comparing SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel (intervention group) to the current gold standard treatment Silvadene (control group). Both groups will receive the same care other than the treating agent. Subjects will be recruited form the UPMC Mercy Burn Center adult patient pool who have sustained superficial partial-thickness burn wounds that comprise less than or equal to 10% of total body surface area (TBSA) |
| NCT04601532 ↗ | Superficial Partial-Thickness Burn Study | Recruiting | J. Peter Rubin, MD | Phase 4 | 2021-06-11 | This study is an investigator initiated, single site, University of Pittsburgh, prospective, parallel group, randomized controlled trial comparing SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel (intervention group) to the current gold standard treatment Silvadene (control group). Both groups will receive the same care other than the treating agent. Subjects will be recruited form the UPMC Mercy Burn Center adult patient pool who have sustained superficial partial-thickness burn wounds that comprise less than or equal to 10% of total body surface area (TBSA) |
| NCT05073172 ↗ | StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients | Not yet recruiting | Oregon Health and Science University | N/A | 2021-11-15 | This clinical trial studies the effect of StrataXRT in preventing and treating radiation dermatitis in breast cancer or head and neck cancer patients. Radiotherapy is often associated with multiple side effects. These side effects can cause patient injury and make it difficult to complete treatment. For example, radiation dermatitis or skin damage may result in severe skin peeling and skin irritation. Depending on the location of radiation, the skin damage can cause problems and be tough to heal. This trial aims to see whether StrataXRT may help to prevent dermatitis after radiation therapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SILVADENE
Condition Name
Clinical Trial Locations for SILVADENE
Trials by Country
Clinical Trial Progress for SILVADENE
Clinical Trial Phase
Clinical Trial Sponsors for SILVADENE
Sponsor Name
